HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares hit a new 52-week low on Wednesday . The company traded as low as $12.89 and last traded at $12.87, with a volume of 4366 shares changing hands. The stock had previously closed at $13.20.
Wall Street Analysts Forecast Growth
Separately, StockNews.com lowered HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
View Our Latest Stock Report on HUTCHMED
HUTCHMED Stock Performance
The stock has a fifty day simple moving average of $14.40 and a two-hundred day simple moving average of $17.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of HCM. Summit Trail Advisors LLC increased its holdings in shares of HUTCHMED by 14.4% during the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after buying an additional 1,647 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after purchasing an additional 1,799 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of HUTCHMED during the third quarter worth about $35,000. Barclays PLC raised its stake in HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after acquiring an additional 2,255 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in HUTCHMED by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock worth $117,000 after acquiring an additional 2,321 shares during the period. 8.82% of the stock is currently owned by institutional investors and hedge funds.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
